DIAGNOSTIC TEST OF MOLECULAR RAPID TEST AGAINST REAL-TIME PCR ON DETECTING BCR-ABL CHRONIC MYELOID LEUKEMIA
Abstrak
Chronic Myeloid Leukemia (CML) is a condition characterized by abnormal proliferation of hematopoietic cells and can occur across various age groups. Detection of Breakpoint Cluster Region-Abelson (BCR-ABL) is essential to identify the presence of the Philadelphia chromosome (Ph 1 chr). Real-Time Polymerase Chain Reaction (Real-Time PCR) is the gold standard for BCR-ABL detection, but it has limitations such as long processing time and high cost. The Molecular Rapid Test (TCM) using the GenXpert platform offers a faster and more practical alternative. This study aimed to evaluate the performance of TCM BCR-ABL compared to Real-Time PCR. A cross-sectional design was applied with 54 samples obtained using consecutive sampling based on Lemeshow’s formula. The results showed a sensitivity of 91%, specificity of 90%, positive predictive value (PPV) of 94%, and negative predictive value (NPV) of 86%. Wilcoxon test analysis revealed no significant difference between the two methods (p=0.100). In conclusion, TCM demonstrates diagnostic performance comparable to Real-Time PCR and has the potential to be used as a rapid and efficient alternative for CML detection.
Artikel teks lengkap
Referensi
2. El-Tanani M, Nsairat H, Matalka II, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254. doi:10.1016/j.prp.2024.155161
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
4. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
5. Smitalova D, Dvorakova D, Racil Z, Romzova M. Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays. Pract Lab Med. 2021;25(January 2020):e00210. doi:10.1016/j.plabm.2021.e00210
6. Budiarto E. Metodologi Penelitian Kedokteran : Sebuah Pengantar. EGC; 2004.
7. Tumbelaka A. Telaah Kritis Makalah Uji Diagnostik. Sari Pediatr. 2016;4:98. doi:10.14238/sp4.2.2002.98-102
8. Azis SI, Tandarto M, Adilah I, et al. Nilai sensitivitas, spesifisitas, nilai duga positif (NDP) dan nilai duga negatif (NDN) tes diagnostik cepat antigen pada skrining pasien Corona Virus Disease-19 (COVID-19) di Poliklinik Fakultas Kedokteran Universitas Mulawarman, Samarinda. J Ked Mulawarman. 2022;9(1):14-23.
9. Permana GP, Rahayu IG, Kurniawan E, Rohayati. Analisis Unit Cost Pemeriksaan Breakpoint Cluster Region - Abelson (BCR-ABL) Dalam Peningkatan Pendapatan Rsup Dr. Hasan Sadikin Bandung. J Med Lab Sci. 2024;4(2). doi:10.36086/medlabscience.v4i2
10. Swift A, Heale R, Twycross A. What are sensitivity and specificity? Evid Based Nurs. 2020;23(1):2-5. doi:10.1136/ebnurs-2019-103225
11. Thermo Fisher Scientific. PCR Basic. Thermo Fisher Scientific Inc. 2016. https://www.thermofisher.com/id/en/home/life-science/cloning/cloning-learning-center/invitrogen-school-of-molecular-biology/pcr-education/pcr-reagents-enzymes/pcr-basics.html
12. Cepheid. Xpert ® BCR-ABL Ultra.; 2022. https://infomine.cepheid.com/sites/default/files/2023-04/Xpert BCR-ABL Ultra Assay-INDONESIAN Package Insert 302-0742-ID Rev. D.pdf
13. Aliviameita A; P. Buku Ajar Mata Kuliah Hematologi. Cetakan pe. (Sartika, Septi B; Multazam M., ed.). UMSIDA Press; 2019.
14. Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagnostics. 2013;15(5):565-576. doi:10.1016/j.jmoldx.2013.04.007
15. Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA. J Mol Diagnostics. 2019;21(4):718-733. doi:10.1016/j.jmoldx.2019.03.002
16. Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagnostics. 2007;9(2):220-227. doi:10.2353/jmoldx.2007.060112
17. More S, Chatterjee T, Agarwal C, Pujani M, Chandoke RK. Fully Automated GeneXpert BCR-ABL1 Assay versus Standard Nonautomated BCR-ABL1 Real-Time Reverse Transcription – Polymerase Chain Reaction Quantitation : A Study from Tertiary Care Institute in India. Published online 2024:1-5. doi:10.4103/jmau.jmau
18. Arora R, Press RD. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. Leuk Lymphoma. 2017;58(1):8-16. doi:10.1080/10428194.2016.1190974
19. Siswosudarmo R. Tes Diagnostik. J Metodol Penelit. 2017;12.
Penulis
Artikel ini berlisensi Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.